Is This Healthcare Stock a Millionaire Maker? [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
significant clinical and regulatory progress, as well as a portfolio of now-approved drugs that generate solid sales. Axsome Therapeutics might only be getting started. The company still has a deep pipeline and plenty of catalysts ahead. But does it have what it takes to turn average investors into millionaires? Lots of moving parts If you had invested $50,000 into Axsome Therapeutics following its IPO, you would be sitting on close to $1 million today, given its compound annual growth rate of 33.32% over this period. Can the biotech pull off a similar performance through the next decade? That's unlikely, as it would give the company a market cap of about $157 billion, making it one of the largest drugmakers in the world. It's not impossible, to be clear, but it's an incredibly high bar to expect Axsome Therapeutics to match the performance it has had since 2015, when it started as a significantly smaller biotech stock Will AI create the world's first trillionaire? Our team just
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (AXSM) had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a "buy" rating on the stock.MarketBeat
- Is This Healthcare Stock a Millionaire Maker? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswire
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswire
- Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 4/1/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 2/27/26 - Form 4
- AXSM's page on the SEC website